ENTA NASDAQ
Enanta Pharmaceuticals, Inc.
1W: +9.1%
1M: -8.0%
3M: -10.7%
YTD: -10.1%
1Y: +22.1%
3Y: +12.7%
5Y: -76.9%
$12.96
+0.12 (+0.93%)
Weekly Expected Move ±7.0%
$11
$12
$13
$14
$15
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2023-04-27
Earliest Filing
2023-04-27
Latest Filing
investor: 2
partner: 1
Counterparties (Filed by ENTA)
3 relationshipsCompanies named in ENTA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| OCM Life Sciences Portfolio LP | — | investor | Purchased 54.5% of Enanta's royalty interest in MAVYRET/MAVIRET for $200 million | 2023-04-27 | View |
| OMERS | — | investor | Parent organization of OCM Life Sciences Portfolio LP | 2023-04-27 | View |
| AbbVie Inc. | ABBV | partner | Holds existing license agreement with Enanta for protease inhibitors | 2023-04-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-23 | Other Events | View | |
| 2026-06-18 | Regulation FD; Exhibits | View | |
| 2026-03-26 | Other Events | View | |
| 2026-03-12 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2026-02-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-01 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-17 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-02-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-09 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR